Takeda Pharmaceutical (TAK) Intangibles (2017 - 2026)

Takeda Pharmaceutical's Intangibles history runs 10 years deep, the most recent figure standing at $21.8 billion for Q1 2026.

• On a quarterly basis, Intangibles fell 8.4% year-over-year to $21.8 billion in Q1 2026; TTM through Mar 2026 was $21.8 billion, a 8.4% decrease from a year earlier, with the FY2026 full-year figure at $22.7 billion, down 4.72% from the prior year.
• Intangibles slipped to $21.8 billion in Q1 2026 per TAK's latest filing, from $22.8 billion in the prior quarter.
• Across five years, Intangibles topped out at $32.9 billion in Q2 2023 and bottomed at $21.8 billion in Q1 2026.
• The 5-year median for Intangibles is $27.7 billion (2023), against an average of $27.5 billion.
• Across the five-year window, Intangibles dropped 20.09% in 2022 and grew 3.98% in 2023, its largest moves.
• Year by year, Intangibles stood at $26.7 billion in 2022, then climbed by 3.98% to $27.7 billion in 2023, then slipped by 6.21% to $26.0 billion in 2024, then fell by 12.12% to $22.8 billion in 2025, then slipped by 4.56% to $21.8 billion in 2026.
• Per Business Quant, the three latest TAK Intangibles figures stand at $21.8 billion (Q1 2026), $22.8 billion (Q4 2025), and $22.4 billion (Q3 2025).